Research
Energy balance
Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 receptor agonist used.
GLP-1 RAs can be considered safe for use in diverse patient populations without increased risk of suicidality.
StrongSupportsmedium confidence
Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 RA used.
Why this rating
Based on the systematic review of randomized clinical trials.
Source
Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity
Pouya Ebrahimi et al. · JAMA Psychiatry · 2025
DOI 10.1001/jamapsychiatry.2025.0091
rct · n=59396Cited 29×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The incidence of completed or attempted suicide and occurrences of suicidal ideation or self-harm is very low in individuals receiving GLP-1 receptor agonists (0.047 per 100 person-years) compared to placebo (0.042 per 100 person-years), with no statistically significant difference.Strong
- There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 receptor agonists within the context of randomized controlled trials.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →